<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309240</url>
  </required_header>
  <id_info>
    <org_study_id>KY-1-2020-07-01</org_study_id>
    <nct_id>NCT04309240</nct_id>
  </id_info>
  <brief_title>Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports</brief_title>
  <official_title>The Efficacy and Safety of Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LiuZhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LiuZhou People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rivaroxaban has been developed in the various clinical settings.Although cancer-associated
      DVT or PE was included in previously programs, limited patients of the total populations were
      cancer patients with totally implantable access ports in these studies. In this sense,
      investigators feel that new oral anticoagulants should be re-investigated in this highly
      specific patients group.Therefore, investigators are planning to conduct a prospective study
      to estimate the efficacy and safety of rivaroxaban for thromboprophylaxis in high-risk cancer
      patients with totally implantable access ports.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 8, 2020</start_date>
  <completion_date type="Anticipated">March 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of venous thrombosis</measure>
    <time_frame>From date of randomization until the date of occurrence of thrombosis or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>detect the occurrence of venous thrombosis with ultrasound, venography if necessary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>occurrence of a major bleeding event.</measure>
    <time_frame>From date of randomization until the date of occurrence of a major bleeding event or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>define occurrence of major-bleeding event with ISTH standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>occurrence of clinically relevant non-major-bleeding, minor-bleeding or non-bleeding event</measure>
    <time_frame>From date of randomization until the date of occurrence of events or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>define occurrence of non-major-bleeding or minor-bleeding event with ISTH standard, evaluate the relevant adverse drug reaction with NCI CTCAE 5.0</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Rivaroxaban</condition>
  <condition>Thromboprophylaxis</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral Rivaroxaban 10mg per day for 90days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>mechanical prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 10mg orally per day for 90days</description>
    <arm_group_label>rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          1. Age 18-75 years;

          2. Patients with malignant tumors who received implantable access ports for treatment;

          3. Eastern Cooperative Oncology Group (ECOG) class 0-1;

          4. will have a life expectancy &gt; 3 months;

          5. Expected survival of more than 6 months;

          6. Khorana score ≥2 point.

        Exclusion Criteria:

          1. Patients with a history of allergies to rivaroxaban;

          2. History of recent major or clinically relevant bleeding within the previous 4 weeks.

          3. Patients with bleeding risks: thrombocytopenia (platelet count &lt; 50*109/L), clinically
             significant active bleeding, active gastric ulcer disease, severe arterial
             hypertension, history of previous stroke; Inadequate renal function; creatinine
             clearance &lt; 30 ml/min；

          4. Inadequate hepatic function: aminotransferase &gt; 3 times the upper limit of normal
             (ULN) (if liver metastasis, alanine aminotransferase &gt; 5 times the ULN

          5. Patients requiring strong cytochrome P450 3A4 (CYP3A4) inducers (rifampin,
             phenobarbital) or strong CYP3A4 inhibitors (HIV protease inhibitor, systemic
             ketoconazole) treatments.

          6. Plan of treatment with bevacizumab or other anti-cancer drugs known to increase the
             bleeding risk.

          7. Patients who have had anticoagulant drugs for any other reason.

          8. Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yu bin, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>LiuZhou People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>liu ting, master</last_name>
    <phone>13978872445</phone>
    <email>liuting201070176@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yu bin, PHD</last_name>
    <phone>13877253868</phone>
    <email>95197586@qq.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.</citation>
    <PMID>30786186</PMID>
  </reference>
  <reference>
    <citation>Wang TF, Zwicker JI, Ay C, Pabinger I, Falanga A, Antic D, Noble S, Khorana AA, Carrier M, Meyer G. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019 Oct;17(10):1772-1778. doi: 10.1111/jth.14564. Epub 2019 Jul 28.</citation>
    <PMID>31353841</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LiuZhou People's Hospital</investigator_affiliation>
    <investigator_full_name>tingliu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prophylactic Anticoagulation</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>venous thrombosis</keyword>
  <keyword>Totally Implantable Access Ports</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

